| 14.71 0.01 (0.07%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.95 | 1-year : | 20.96 |
| Resists | First : | 15.36 | Second : | 17.95 |
| Pivot price | 14.65  |
|||
| Supports | First : | 14.31 |
Second : | 13.67 |
| MAs | MA(5) : | 14.82  |
MA(20) : | 14.48 |
| MA(100) : | 16.18 |
MA(250) : | 17.38 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 61 |
D(3) : | 65 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 21.23 | Low : | 13.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MDWD ] has closed below upper band by 49.2%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.92 - 14.99 | 14.99 - 15.05 |
| Low: | 14.33 - 14.41 | 14.41 - 14.47 |
| Close: | 14.58 - 14.71 | 14.71 - 14.81 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Sat, 04 Jul 2026
Enterprise value to EBITDA forward of MediWound Ltd. – NASDAQ:MDWD - TradingView
Sun, 28 Jun 2026
MediWound Ltd.(NasdaqGM: MDWD) added to Russell 2000 Value-Defensive Index - marketscreener.com
Wed, 17 Jun 2026
Mediwound Ltd (MDWD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Thu, 04 Jun 2026
Insider Buying: Nachum Shamir Acquires 6,000 Shares of MediWound Ltd (MDWD) - GuruFocus
Tue, 02 Jun 2026
MediWound (MDWD) director buys 3,537 ordinary shares on open market - Stock Titan
Wed, 27 May 2026
Oppenheimer lowers MediWound stock price target to $32 on revenue miss - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 15.8 (%) |
| Held by Institutions | 58.2 (%) |
| Shares Short | 1,690 (K) |
| Shares Short P.Month | 1,510 (K) |
| EPS | -2.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.22 |
| Profit Margin | -180.4 % |
| Operating Margin | -541.1 % |
| Return on Assets (ttm) | -23.6 % |
| Return on Equity (ttm) | -71.9 % |
| Qtrly Rev. Growth | -62.8 % |
| Gross Profit (p.s.) | 0.22 |
| Sales Per Share | 1.12 |
| EBITDA (p.s.) | -2.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -6.49 |
| PEG Ratio | 0 |
| Price to Book value | 4.55 |
| Price to Sales | 13.01 |
| Price to Cash Flow | -10.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|